Device Trial Radar · NCT04510714
BORIS - aBlação pOR mIcro-ondaS [Microwave Ablation]
Last checked: Nov 19, 2026Latest source record: Aug 3, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
60
Planned (sponsor's estimate)
Start
Jun 1, 2023
Primary completion
Apr 1, 2025
Study completion Oct 1, 2025
Sponsor
- Lead sponsor
- Instituto do Cancer do Estado de São PauloAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Angiodynamics, Inc.
- First posted
- Aug 12, 2020
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Patients with sarcoma and lung metastases have few therapeutic options, with poor response to systemic treatment. Many of them are not eligible to surgical treatments due to the high number and distribution of pulmonary lesions or due to comorbidities, which reduce the survival chances of these individuals. Given the high efficacy and overall increased survival demonstrated by recent studies, the minimally invasive treatments (mainly radiofrequency ablation) have gained ground. Although the microwave ablation is a promising new technique for the treatment of patients with pulmonary metastases, there are few studies in the literature to evaluate the efficacy and safety of this procedure in the above population.
Conditions
- Sarcoma
Interventions
Image guided percutaneous microwave ablationDevice
Lung metastasis from sarcoma will be treated with microwave antennas (SOLERO) and Ablation System and microwave generators (Angiodynamics), with power settings of 35-45W and an average ablation time of 15 minutes (range 10-30 minutes). The ablation time will be recorded for all procedures. The manufacturer's recommendations will be observed in all cases, since it is assured that patients are able to tolerate the total ablation time.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall SurvivalTime frame: 3 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Instituto do Câncer do Estado de São Paulo
São Paulo, Brazil · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.